Michael McCaughan
It doesn’t sound like news: Kos Pharmaceuticals Inc. ’s sustained-release niacin brand Niaspan and Upsher-Smith Laboratories Inc. ’s...
CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.
More from Market Access
• By
The suits are an early test of the Arkansas law banning company ownership of PBMs and pharmacies in the state, as other states consider similar legislation.
• By
An unintended consequence of a provision framed as an administrative change in the bill could significantly reduce medication adherence among low-income older adults and increase mortality, a study found.
• By
Despite pushback by industry, the government is standing by its new statutory scheme rebate rates for branded medicines, including one that doubles the rate that companies must repay on the sales of newer products to the National Health Service to 31.3%.
• By
Companies operating in Argentina may get their medicines to the market more quickly thanks to new updates to the medicines authorization system.
More from Pink Sheet
• By
EU authorities must “take advantage” of the upcoming Biotech Act to reassess the bloc’s policies and “offset existing challenges” for small and midsized enterprises, trade association EUCOPE has said.
• By
The whole contract research organization industry is being impacted by the current volatility in the pharmaceutical industry.
• By
The 14 July deadline for the Citeline Japan Awards 2025 in Tokyo is approaching fast, so here's a reminder to take a look at the categories and criteria and be sure to get your submissions in by this date. Sponsorship opportunities and tables for the event are also available.